KYinno

KYinno is an innovative technology platform company focused on new drug research and development services. It was co-founded by a team of scientists with many years of experience working at internationally renowned CROs and biotechnology companies. Headquartered in Beijing Economic-Technological Development Area, the company also has a business office in the United States. Since its establishment, KYinno has been committed to building a technology platform for innovative drug research and development. The company has constructed the industry's largest library of genetically engineered cells, developed a mature GPCR antibody discovery platform, and created platforms for nanobodies, bispecific antibodies, gene-edited mice, and a defective CHO cell expression system. Based on these achievements, KYinno provides comprehensive technical services including the discovery and validation of new drug targets, screening and discovery of antibodies and small molecule drugs, and pharmacology and efficacy studies, supporting clients in their innovative drug research and development for both large-molecule antibodies and small-molecule chemical drugs. With a global focus, KYinno has established strong cooperative relationships with over 200 domestic and international clients since its inception, including several top-ten multinational pharmaceutical companies.